The MyCode Community Health Initiative has consented more than 112,000 Geisinger patients who will provide blood and/or tissue samples to be genetically sequenced. That data will be combined with each participant's medical record to provide Geisinger researchers with information to investigate new approaches to disease control, diagnosis and treatment. The study uses a broad consent and includes the ability to re-contact participants and share medically actionable results. Questions about the project can be directed to Andy Faucett, MS, LGC, at email@example.com or 570-214-4862.
As part of a partnership with Regeneron Pharmaceuticals, MyCode plans to collect samples from more than 250,000 consented patients, whose de-identified genomic data will help to improve patient care and speed drug discovery and development.